# Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

> **NCT03821246** · PHASE2 · RECRUITING · sponsor: **David Oh** · enrollment: 68 (estimated)

## Conditions studied

- Prostate Adenocarcinoma
- Prostate Cancer
- Localized Prostate Cancer

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Tocilizumab
- **DRUG:** Etrumadenant

## Key facts

- **NCT ID:** NCT03821246
- **Lead sponsor:** David Oh
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-10-30
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-04-30
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2025-05-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03821246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03821246, "Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03821246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*